INOVIO Seeks European Approval for HPV-Related Therapy
PLYMOUTH MEETING, PA — INOVIO Pharmaceuticals (NASDAQ: INO) has applied for conditional marketing authorization in Europe for VOCERYQ, its recently approved DNA-based immunotherapy for recurrent respiratory papillomatosis, seeking to expand …
INOVIO Seeks European Approval for HPV-Related Therapy Read More